Vitiligo, New Treatment and Serum s100B
ConditionVitiligo, Generalized
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age10-75
SponsorSouth Valley University
About this trial
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem.
Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Eligibility criteria
Qualifiers
active generalized vitiligo patients with body surface area involved >5% excluding hands and feet
no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks.
Disqualifiers
acrofacial, acral, segmental or mucosal vitiligo
patients on another immunosuppressive agent
patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo.
patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma)
Trial design
Treatments tested in this trial
- Baricitinib
- oral mini pulse
- Narrow Band UVB Treatment
Treatment groups
50 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov